Medicus Pharma Ltd..
MDCX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Medicus Pharma Ltd. is a pharmaceutical company focused on the development, manufacturing, and commercialization of generic and specialty pharmaceutical products. The company's portfolio includes a range of prescription and over-the-counter medications across various therapeutic areas. Medicus Pharm...Show More
Better Health for All
0
Medicus Pharma's core business is dedicated to health improvement, focusing on developing treatments for conditions such as equine squamous cell carcinoma, basal cell carcinoma, advanced prostate cancer, and acute urinary retention (AUR) prevention. The company has reported a strong safety record for its D-MNA treatment, with a Phase 1 human study (SKNJCT-001) showing no dose-limiting toxicities or serious adverse events.
1
For its D-MNA treatment, the company holds patent protection and has received a Minor Use in Major Species (MUMS) designation, which grants a 7-year exclusive marketing period.
2
The company conducts randomized, double-blind, placebo-controlled clinical studies, including a planned study (SKNJCT-004) for equine SCC and ongoing Phase 2 studies (SKNJCT-003) for basal cell carcinoma in the US and Europe, and another study (SKNJCT-004) in the UAE.
3
The acquisition of Antev Ltd. also involves assets in FDA-approved Phase 2b studies.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Medicus Pharma Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Medicus Pharma Ltd. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Medicus Pharma Ltd. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Medicus Pharma Ltd. on Honest & Fair Business.
Kind to Animals
-30
Medicus Pharma Ltd. is conducting clinical studies involving animals.
1
Specifically, the SKNJCT-004 clinical study is designed to enroll up to 50 horses.
2
The company is developing a non-invasive treatment for equine Squamous Cell Carcinoma (SCC) using a microneedle array patch.
3
Medicus Pharma has received a Minor Use in Major Species Designation (MUMS) from the FDA for its Doxorubicin-containing microneedle array (D-MNA) for horses and has submitted product development plans and clinical protocols to the FDA.
4
However, the company does not have a public position on animal welfare legislation and is silent on industry standards.
No War, No Weapons
0
Medicus Pharma Ltd. is described as a pharmaceutical company focused on developing and commercializing generic and specialty pharmaceutical products.
1
The company's activities, as detailed in the articles, primarily involve clinical studies, drug development, and strategic collaborations for patient access to therapies.
2
There is no evidence in the provided articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to sanctioned regimes, or any other activities related to the 'No War, No Weapons' ethical value. Mentions of AI are for clinical data analytics, and microneedle arrays are for medical applications.
3
Clinical studies in the UAE do not indicate sales to an embargoed regime.
4
Therefore, all KPIs are scored as N/A (0) due to a lack of relevant information.
Planet-Friendly Business
0
No sustainability data or information relevant to planet-friendly business practices for Medicus Pharma Ltd. (MDCX.US) was found in the provided articles.
1
Therefore, no KPIs could be scored.
Respect for Cultures & Communities
0
No specific, concrete data points or facts relevant to Medicus Pharma Ltd.'s (MDCX.US) performance on 'Respect for Cultures & Communities' were found in the provided articles. The articles primarily focus on corporate governance, investor relations, general business benefits of DEI, or clinical trial submissions, explicitly stating a lack of information regarding community relations, partnerships, cultural impact assessments, employment ratios, grievance mechanisms, or any other related social responsibility indicators.
1
Safe & Smart Tech
0
No evidence available to assess Medicus Pharma Ltd. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points for Medicus Pharma Ltd. (MDCX.US) related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles. The articles discuss general pharmaceutical waste management practices, regulatory frameworks in specific regions, or company structure and leadership without providing relevant sustainability metrics for MDCX.US.